BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30

• Press Releases

  Truvian Health Receives another FDA Clearance – for Complete Blood Count (CBC) on TruVerus™

  January 21, 2026

   · 

  4 min read
• Press Releases

  Charles River Enters Manufacturing Collaboration with Gazi University

  January 21, 2026

   · 

  2 min read
• Press Releases

  Odyssey Therapeutics Appoints Jolie M. Siegel as Executive Vice President, General Counsel

  January 21, 2026

   · 

  3 min read
• Press Releases

  U.S. FDA Grants to Wugen’s WU-CART-007 Breakthrough Therapy Designation for Treatment of Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia / T Cell Lymphoblastic Lymphoma

  January 21, 2026

   · 

  4 min read
• Press Releases

  Soley Therapeutics Announces Breakthrough Research Demonstrating How Cellular Stress Responses Reveal Drug Mechanisms, Enabling Entirely New and Accelerated Methods for Drug Discovery

  January 21, 2026

   · 

  3 min read
• Press Releases

  Defence Therapeutics Sharpens Strategic Focus on Precision Drug Delivery to Unlock the Full Potential of Cancer Biologics

  January 21, 2026

   · 

  4 min read
• 

  Business

  JPM26: KalVista’s HAE Win Is a ‘Tale of Two Markets’

  After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.

  January 21, 2026

   · 

  3 min read

   · 

  Dan Samorodnitsky
• 

  C-suite

  JPM26: Filling C-Suites, Union Square—and Elevators—With Pink

  Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.

  January 21, 2026

   · 

  2 min read

   · 

  Annalee Armstrong
• 

  Earnings

  J&J Aims for $100B in Sales, Puts Stelara Patent Cliff ‘in the Rearview Mirror’

  Reporting Q4 and full year earnings on Wednesday, J&J executives hailed growth across the healthcare giant’s portfolio while standing fast on its talc lawsuit and tariffs.

  January 21, 2026

   · 

  2 min read

   · 

  Dan Samorodnitsky